Final-Program-ATS-2023-AP.vp

WEDNESDAY • MAY 24

329

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NIH OUTSIDE ORGANIZATION SESSION

DIVISION OF LUNG DISEASES, NHLBI/NIH OUTSIDE ORGANIZATION SESSION

L28 COPDGENE: ADVANCES IN COPD HETEROGENEITY AND PROGRESSION 10:30 AM - 11:30 AM Walter E. Washington Convention Center Room 143 A-C (Street Level) Target Audience Researchers, medical trainees, those with an interest in COPD pathogenesis Objectives At the conclusion of this session, the participant will be able to: • learn about aging and mortality in the COPDGene study • learn about COPD progression in the COPD study • learn about reclassification of COPD in the COPDGene study Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the United States in 2019, is a heterologous syndrome. The COPDGene study has created the largest cohort of well-characterized current and former smokers for respiratory disease research. The primary goals of COPDGene are: 1) to identify new genetic loci that influence the development of COPD and COPD-related phenotypes and 2) to reclassify COPD into subtypes that can ultimately be used to develop effective therapies. In this session, presenters will discuss new results from the COPDGene study, including new ways to diagnose the disease, deep learning approaches to imaging data, genetics, epigenetics, transcriptomics, proteomics, and an integrative Omics approach. Chairing: L. Postow, PhD, Bethesda, MD J.D. Crapo, MD, Denver, CO 10:30 Progression of COPD by Chest CT S. Ash, MD, Boston, United States 10:42 Mortality in COPDGene W.W. Labaki, MD, MS, Ann Arbor, MI 10:54 Cognitive Decline and Aging K.F. Hoth, PhD, Iowa City, IA 11:06 Metabolomics and COPD Progression S. Godbole, PhD, Denver, United States 11:18 Reclassifying COPD G.L. Kinney, MPH, PhD, Aurora, CO

L27 AIRWAY OMICS FOR DISEASE ENDOTYPING AND MANAGEMENT 10:30 AM - 11:30 AM Walter E. Washington Convention Center Room 145 A-B (Street Level) Target Audience Clinical researchers and clinicians Objectives At the conclusion of this session, the participant will be able to: • describe new findings relating nasal airway transcriptomic signatures with disease outcomes in data obtained as part of a randomized placebo-controlled trial of mepolizumab in urban children with exacerbation prone asthma. • describe the lower airway immune response in patients with severe COVID-19, compare transcriptomic signatures from upper and lower airways in these patients, and identify airway immune signatures associated with disease severity • describe approaches to integrate nasal transcriptomic and microbiome data in infants with respiratory bronchiolitis to identify endotypes associated with asthma development. This session will describe results from 3 NIAID-funded programs that utilize omics data collected from the upper and/or lower airway to define disease endotypes, to potentially inform personalized medicine approaches to disease prognosis and/or management. Chairing: P.M. Becker, MD, Bethesda, MD 10:30 Using Airway Transcriptomics to Identify Pathways Associated with Exacerbation and Responsiveness to Mepolizumab Therapy in Children M.C. Altman, MD, MPhil, Seattle, WA 10:50 Integrated Analysis of Airway Immune Responses in Severe COVID-19: Results from the IMPACC Cohort R.R. Montgomery, PhD, New Haven, CT 11:10 Integrated Omics Investigation into the Mechanisms Linking Severe Bronchiolitis During Infancy and the Development of Asthma K. Hasegawa, MD, MPH, PhD, Boston, MA

ATS 2023 • Washington, DC